1. (R)-1 for DNK-333 (neurokinin NK1/NK2 receptor antagonist; Novartis), Gerspacher, M., 223rd ACS National Meeting (April 7–11, Orland) 2002, Abst MEDI-139; Daily Drug News, April 15, 2002
2. (S)-1 for RU-81843, RU-84687 (nonpeptide Src SH2-binding compounds for osteoporosis; Aventis), Deprez, P. et al., 16th Intl. Symp Med. Chem. (Sep. 18–22, Bologna) 2000, Abst. PA-17; Daily Drug News Sep. 21, 2000
3. (S)-1 for caprolactam carbonates with antitumor activity (oncolytic drug, Novartis), WO 0185697; Daily Drug News, Jan. 9, 2002
4. (S)-1 for Src kinase SH2 antagonist (metabolic drug, Ariad), WO 0168655; Daily Drug News, Oct. 31, 2001.
5. Sifniades, S. Chirality in Industry; Collins, A. N.; Sheldrake, G. N.; Crosby, J., Eds. l-Lysine via asymmetric transformation of α-amino-ε-caprolactam; John Wiley & Sons, 1992; pp. 79–86.